[18F]AlF-NOTA-奥曲肽 PET 显像:生物分布、剂量学及与[68Ga]Ga-DOTATATE 在神经内分泌肿瘤患者中的首次比较
本前瞻性试验在 6 名健康志愿者和 6 名神经内分泌肿瘤患者中评估了[18F]AlF-NOTA-奥曲肽([18F]AlF-OC)的安全性、剂量学、生物分布、药代动力学和病灶靶向性,并与[68Ga]Ga-DOTATATE 进行首次比较。[18F]AlF-OC 给药安全且耐受良好,有效剂量为 22.4 ± 4.4 μSv/MBq,生理性摄取模式与[68Ga]Ga-DOTATATE 相当;肿瘤 SUVmax 较低(2 小时 12.3 ± 6.5 vs. 18.3 ± 9.5,p = 0.03),但 TBR 和检出率无显著差异。
要点
- [18F]AlF-OC 给药安全且耐受良好,有效剂量为 22.4 ± 4.4 μSv/MBq。
- 脾脏吸收剂量最高(0.159 ± 0.062 mGy/MBq),其次为膀胱壁和肾脏。
- 2 小时肿瘤 SUVmax 较低(12.3 ± 6.5 vs. 18.3 ± 9.5,p = 0.03),但 TBR 和检出率无显著差异。
核心结论
- [18F]AlF-OC 在患者中显示出良好的动力学和显像特征,需进一步头对头比较以验证其作为镓-68 标记生长抑素类似物临床 PET 的氟-18 标记替代方案。
研究设计与样本
- 前瞻性试验纳入 6 名健康志愿者和 6 名既往接受过临床[68Ga]Ga-DOTATATE PET 的神经内分泌肿瘤患者,静脉推注 4 MBq/kg [18F]AlF-OC。
- 健康志愿者自注射时至注射后 90 分钟行系列全身 PET 扫描,并在注射后 150 和 300 分钟额外行 PET/CT。
- 患者行动态 PET 45 分钟,并在注射后 60、90 和 180 分钟行三次全身 PET 扫描。
主要发现
- [18F]AlF-OC 给药安全且耐受良好。
- 脾脏吸收剂量最高(0.159 ± 0.062 mGy/MBq),其次为膀胱壁(0.135 ± 0.046 mGy/MBq)和肾脏(0.070 ± 0.018 mGy/MBq)。
- 有效剂量为 22.4 ± 4.4 μSv/MBq。
- [18F]AlF-OC 的生理性摄取模式与[68Ga]Ga-DOTATATE 相当。
- 注射后 2 小时平均肿瘤 SUVmax 较低:[18F]AlF-OC 12.3 ± 6.5 vs. [68Ga]Ga-DOTATATE 18.3 ± 9.5(p = 0.03);TBR 无显著差异:[18F]AlF-OC 9.8 ± 6.7 vs. [68Ga]Ga-DOTATATE 13.6 ± 11.8(p = 0.35);检出率:[68Ga]Ga-DOTATATE 86.0% vs. [18F]AlF-OC 90.1%(p = 0.68)。
关键数值与推荐
- 脾脏吸收剂量 0.159 ± 0.062 mGy/MBq,膀胱壁 0.135 ± 0.046 mGy/MBq,肾脏 0.070 ± 0.018 mGy/MBq。
- 有效剂量 22.4 ± 4.4 μSv/MBq。
- 2 小时肿瘤 SUVmax:[18F]AlF-OC 12.3 ± 6.5 vs. [68Ga]Ga-DOTATATE 18.3 ± 9.5(p = 0.03)。
- 2 小时 TBR:[18F]AlF-OC 9.8 ± 6.7 vs. [68Ga]Ga-DOTATATE 13.6 ± 11.8(p = 0.35),无显著差异。
- 检出率:[68Ga]Ga-DOTATATE 86.0% vs. [18F]AlF-OC 90.1%(p = 0.68),无显著差异。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文结论指出需进一步头对头比较以验证[18F]AlF-OC 作为镓-68 标记生长抑素类似物临床 PET 的氟-18 标记替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The widespread use of gallium-68-labelled somatostatin analogue (SSA) PET, the current standard for somatostatin receptor (SSTR) imaging, is limited by practical and economic challenges that could be overcome by a fluorine-18-labelled alternative, such as the recently introduced [18F]AlF-NOTA-octreotide ([18F]AlF-OC). This prospective trial aimed to evaluate safety, dosimetry, biodistribution, pharmacokinetics and lesion targeting of [18F]AlF-OC and perform the first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour (NET) patients. METHODS: Six healthy volunteers and six NET patients with a previous clinical [68Ga]Ga-DOTATATE PET were injected with an IV bolus of 4 MBq/kg [18F]AlF-OC. Healthy volunteers underwent serial whole-body PET scans from time of tracer injection up to 90 min post-injection, with an additional PET/CT at 150 and 300 min post-injection. In patients, a 45-min dynamic PET was acquired and three whole-body PET scans at 60, 90 and 180 min post-injection. Absorbed organ doses and effective doses were calculated using OLINDA/EXM. Normal organ uptake (SUVmean) and tumour lesion uptake (SUVmax and tumour-to-background ratio (TBR)) were measured. A lesion-by-lesion analysis was performed and the detection ratio (DR), defined as the fraction of detected lesions was determined for each tracer. RESULTS: [18F]AlF-OC administration was safe and well tolerated. The highest dose was received by the spleen (0.159 ± 0.062 mGy/MBq), followed by the urinary bladder wall (0.135 ± 0.046 mGy/mBq) and the kidneys (0.070 ± 0.018 mGy/MBq), in accordance with the expected SSTR-specific uptake in the spleen and renal excretion of the tracer. The effective dose was 22.4 ± 4.4 μSv/MBq. The physiologic uptake pattern of [18F]AlF-OC was comparable to [68Ga]Ga-DOTATATE. Mean tumour SUVmax was lower for [18F]AlF-OC (12.3 ± 6.5 at 2 h post-injection vs. 18.3 ± 9.5; p = 0.03). However, no significant differences were found in TBR (9.8 ± 6.7 at 2 h post-injection vs. 13.6 ± 11.8; p = 0.35). DR was high and comparable for both tracers (86.0% for [68Ga]Ga-DOTATATE vs. 90.1% for [18F]AlF-OC at 2 h post-injection; p = 0.68). CONCLUSION: [18F]AlF-OC shows favourable kinetic and imaging characteristics in patients that warrant further head-to-head comparison to validate [18F]AlF-OC as a fluorine-18-labelled alternative for gallium-68-labelled SSA clinical PET. TRIAL REGISTRATION: Clinicaltrials.gov : NCT03883776, EudraCT: 2018-002827-40.
引用
- Pauwels E, Cleeren F, Tshibangu T, et al. [18F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 32617641. doi:10.1007/s00259-020-04918-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。